On June 18, Pfizer fell 3.03% in regular trading, trading at $25.095/share, with turnover of $5.58 billion. The decline was triggered by the announcement that Chief Financial Officer Dave Denton will officially depart on August 15 to pursue opportunities in the consumer products industry.

Pfizer has appointed Cecile Guegan as interim CFO. Denton joined Pfizer in 2022 to oversee financial operations, having previously served as CFO at Lowe's and CVS Health, bringing extensive large-enterprise financial management experience. The sudden departure of a core executive has intensified market concerns over management stability at the pharmaceutical giant.

The broader pharmacy sector also traded under pressure, with peers including Johnson & Johnson down 2.43%, Merck down 2.53%, Bristol-Myers Squibb down 2.64%, Novo-Nordisk down 1.36%, and Eli Lilly down 0.93%, compounding the negative sentiment around Pfizer shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)